Actualización normativa

Σε αυτό το σύντομο βίντεο ανακαλύψτε τη Dr. Cheng να αναλύει την αξία της Real World Evidence μελέτης DELIVER-G , σε ανεπαρκώς ρυθμισμένους ασθενείς με ΣΔ τύπου 2 υπό αγωγή με GLP-1-RΑs.

Σε αυτό το σύντομο βίντεο ανακαλύψτε τη Dr. Cheng να εξηγεί ποιες είναι οι παράμετροι που λαμβάνει υπόψη κατά την επιλογή βασικής ινσουλίνης για άτομα με διαβήτη τύπου 2 που δεν ελέγχονται επαρκώς με αγωνιστή υποδοχέα GLP-1.

Παρακολουθήστε on demand το webinar που πραγματοποιήθηκε στις 10 Σεπ 2025.

Fabry disease is an X-linked lysosomal storage disease due to a defect in the gene encoding the lysosomal enzyme alpha-galactosidase A (α-Gal A), causing progressive cellular accumulation of the substrate globotriaosylceramide (GL-3) and globo-triaosylsphingosine (lyso-GL-3).

Fabry disease is an X-linked lysosomal storage disease due to a defect in the gene encoding the lysosomal enzyme alpha-galactosidase A (α-Gal A), causing progressive cellular accumulation of the substrate globotriaosylceramide (GL-3) and globo-triaosylsphingosine (lyso-GL-3).

Fabry disease is an X-linked lysosomal storage disease due to a defect in the gene encoding the lysosomal enzyme alpha-galactosidase A (α-Gal A), causing progressive cellular accumulation of the substrate globotriaosylceramide (GL-3) and globo-triaosylsphingosine (lyso-GL-3).

Fabry disease is an X-linked lysosomal storage disease due to a defect in the gene encoding the lysosomal enzyme alpha-galactosidase A (α-Gal A), causing progressive cellular accumulation of the substrate globotriaosylceramide (GL-3) and globo-triaosylsphingosine (lyso-GL-3).

Fabry disease is an X-linked lysosomal storage disease due to a defect in the gene encoding the lysosomal enzyme alpha-galactosidase A (α-Gal A), causing progressive cellular accumulation of the substrate globotriaosylceramide (GL-3) and globo-triaosylsphingosine (lyso-GL-3).

Think Fabry, think timely testing first.

Think Fabry, think timely testing first.